Stockscreener 앱 받기
16.39
3.34%
0.53
시간 외 거래:
16.38
-0.01
-0.06%
전일 마감가:
$15.86
열려 있는:
$15.86
하루 거래량:
536.26K
Relative Volume:
2.56
시가총액:
$545.91M
수익:
$65.42M
순이익/손실:
$-32.96M
주가수익비율:
-12.91
EPS:
-1.27
순현금흐름:
$-19.87M
1주 성능:
+5.95%
1개월 성능:
-0.06%
6개월 성능:
+57.75%
1년 성능:
+37.38%
1일 변동 폭
$15.81
$17.10
1주일 범위
$15.03
$17.10
52주 변동 폭
$7.5625
$18.98
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
NPCE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
16.39 | 528.26M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
127.78 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.79 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
366.39 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.31 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.85 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
Why NeuroPace Inc. stock remains undervalued2026 world cup usa national team round of 16 defensive leaders pressing system knockout prediction breakdown - Улправда
Responsive Playbooks and the NPCE Inflection - Stock Traders Daily
FOMO Trade: Is NeuroPace Inc stock oversold or undervalued2025 Pullback Review & Low Risk High Win Rate Picks - moha.gov.vn
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Is NeuroPace Inc. stock a buy on dipsPrice Momentum Alerts & Grow Steadily With Our Wealth Roadmap - bollywoodhelpline.com
Published on: 2025-12-25 19:47:27 - moha.gov.vn
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily
How resilient is NeuroPace Inc. stock in market downturns2025 Market WrapUp & Long Hold Capital Preservation Tips - bolumsonucanavari.com
Reviewing NeuroPace (NASDAQ:NPCE) & PROCEPT BioRobotics (NASDAQ:PRCT) - Defense World
Why NeuroPace Inc. stock attracts global investorsInflation Watch & Weekly Watchlist for Hot Stocks - Улправда
How NeuroPace Inc. stock performs in rate cut cycles2025 Earnings Impact & Weekly Watchlist for Consistent Profits - DonanımHaber
Is NeuroPace Inc. stock attractive for growth ETFs2025 Buyback Activity & Risk Controlled Daily Plans - Улправда
Can NeuroPace Inc. stock deliver sustainable ROEWatch List & Fast Entry and Exit Trade Plans - Улправда
Is NeuroPace Inc. stock oversold or undervaluedTrade Exit Report & Expert Curated Trade Ideas - DonanımHaber
Will NeuroPace Inc. stock outperform growth indexes2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Will NeuroPace Inc. stock benefit from green energy trendsWeekly Trade Report & Entry and Exit Point Strategies - DonanımHaber
Aug Rallies: Can NeuroPace Inc. stock deliver sustainable ROETrade Performance Summary & Weekly High Conviction Trade Ideas - ulpravda.ru
Lake Street Keeps Their Buy Rating on NeuroPace (NPCE) - The Globe and Mail
UBS Group Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - Defense World
NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment - Investing.com Nigeria
Is It Time To Consider Buying NeuroPace, Inc. (NASDAQ:NPCE)? - Yahoo Finance
NeuroPace Files FDA Application to Expand RNS System Use - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy - Investing News Network
Neuropace files PMA supplement to FDA - marketscreener.com
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS - Business Wire
UBS Maintains NeuroPace (NPCE) Buy Recommendation - Nasdaq
UBS Adjusts NeuroPace Price Target to $22 From $18, Maintains Buy Rating - marketscreener.com
UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00 - MarketBeat
Wells Fargo Sticks to Their Buy Rating for NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Price Target Raised to $20.00 at JPMorgan Chase & Co. - Defense World
NeuroPace price target raised to $20 from $18 at JPMorgan - MSN
Bank Watch: How buybacks impact NeuroPace Inc stock value2025 Biggest Moves & AI Forecast Swing Trade Picks - moha.gov.vn
JP Morgan Raises Price Target for NPCE to $20.00, Maintains Over - GuruFocus
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price - MarketBeat
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting - MSN
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy - Investing.com UK
NeuroPace stock rises on positive NAUTILUS trial results, UBS reiterates Buy By Investing.com - Investing.com South Africa
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy - BioSpace
Neuropace shows 77% reduction in seizures - BioWorld MedTech
NeuroPace reports 77% seizure reduction in epilepsy device trial - Investing.com
NeuroPace reports 77% seizure reduction in epilepsy device trial By Investing.com - Investing.com Canada
Neuropace announces positive 18-month NAUTILUS trial results in idiopathic generalized epilepsy - marketscreener.com
NeuroPace, Inc. $NPCE Shares Acquired by Divisadero Street Capital Management LP - MarketBeat
Is NeuroPace Stock Built to Withstand a Pullback? - Trefis
MACD Signal: Will USCF ETF Trust USCF Sustainable stock attract long term capital inflowsJuly 2025 Analyst Calls & Reliable Intraday Trade Plans - BỘ NỘI VỤ
NeuroPace Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Panagora Asset Management Inc. Makes New $1.11 Million Investment in NeuroPace, Inc. $NPCE - MarketBeat
Will NeuroPace Inc. stock deliver consistent dividendsEarnings Growth Summary & Reliable Price Breakout Signals - Newser
Published on: 2025-12-04 13:47:14 - Newser
Is NeuroPace Inc. stock ready for breakoutJuly 2025 Summary & Free Long-Term Investment Growth Plans - Newser
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.82%
자본화:
|
볼륨(24시간):